← Back to Search

Radiation Therapy

Radiation Therapy for Non-Small Cell Lung Cancer

Phase 3
Waitlist Available
Led By Puneeth Iyengar, MD
Research Sponsored by University of Texas Southwestern Medical Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 2 years
Awards & highlights

Study Summary

This trial will compare two types of radiation therapy for patients with stage II-III non-small cell lung cancer.

Eligible Conditions
  • Non-Small Cell Lung Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~2 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 2 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Non-Small Cell Lung Carcinoma
Secondary outcome measures
Cost Effectiveness of Two Radiotherapy Treatment Regimens in Patients With Stage II-III NSCLC and Poor Performance Status.
Disease-free Survival of Two Radiotherapy Treatment Regimens in Patients With Stage II-III NSCLC and Poor Performance Status.
Quality Adjusted Life Survival Time of Two Radiotherapy Treatment Regimens in Patients With Stage II-III NSCLC and Poor Performance Status.
+3 more

Trial Design

2Treatment groups
Active Control
Group I: Radiation TherapyActive Control1 Intervention
Arm A:Image-Guided Radiation Therapy (IGRT), 60 Gy in 15 fractions in 3 weeks
Group II: Conventional RadiationActive Control1 Intervention
Arm B: Conventional radiation 60-66 Gy in 30-33 fractions in 6-7 weeks

Find a Location

Who is running the clinical trial?

University of Texas Southwestern Medical CenterLead Sponsor
1,047 Previous Clinical Trials
1,053,696 Total Patients Enrolled
Puneeth Iyengar, MDPrincipal Investigatorpuneeth.iyengar@utsouthwestern.edu
5 Previous Clinical Trials
40,039 Total Patients Enrolled

Media Library

Hypofractionated Image-Guided Radiation Therapy (IGRT) (Radiation Therapy) Clinical Trial Eligibility Overview. Trial Name: NCT01459497 — Phase 3
Non-Small Cell Lung Cancer Research Study Groups: Radiation Therapy, Conventional Radiation
Non-Small Cell Lung Cancer Clinical Trial 2023: Hypofractionated Image-Guided Radiation Therapy (IGRT) Highlights & Side Effects. Trial Name: NCT01459497 — Phase 3
Hypofractionated Image-Guided Radiation Therapy (IGRT) (Radiation Therapy) 2023 Treatment Timeline for Medical Study. Trial Name: NCT01459497 — Phase 3

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Could you please list some of the risks associated with Radiation Therapy?

"Although it is a Phase 3 trial, meaning that there is some data supporting efficacy, there is also multiple rounds of data supporting safety, leading our team at Power to estimate the safety of Radiation Therapy to be a 3."

Answered by AI

Could I go through the process of this research study?

"The requirements to take part in this experiment are that the individual has a diagnosis of lung cancer and is between 18 and 99 years old. Up to 103 people can be enrolled in the trial."

Answered by AI

Are there many sites in Canada that are participating in this trial?

"To make it more convenient for patients, the trial is currently enrolling at 7 locations. These sites are in Irving, Tyler, Austin, and 7 other cities. If you are thinking about participating in the trial, select the location nearest to you to cut down on travel time."

Answered by AI

Are we still accepting participants for this research?

"The clinicaltrials.gov website shows that this study is no longer looking for new patients. This particular trial was first posted on 10/1/2012 but was most recently updated on 5/11/2022. Although this study has completed recruitment, there are 1984 other studies that are actively recruiting patients."

Answered by AI

Is this research project available to patients who are over 35 years old?

"The age requirements to participate in this clinical trial are between 18 to 99 years old."

Answered by AI
Recent research and studies
JAMA OncologyJournal
Accelerated Hypofractionated Image-guided Vs Conventional Radiotherapy for Patients with Stage II/III Non–small Cell Lung Cancer and Poor Performance Status
Iyengar, Puneeth, Elizabeth Zhang-Velten, Laurence Court, Kenneth Westover, Yulong Yan, Mu-Han Lin, Zhenyu Xiong, et al.. 2021. “Accelerated Hypofractionated Image-guided Vs Conventional Radiotherapy for Patients with Stage II/III Non–small Cell Lung Cancer and Poor Performance Status”. JAMA Oncology. American Medical Association (AMA). doi:10.1001/jamaoncol.2021.3186.
JAMA OncologyJournal
Accelerated Hypofractionated Image-guided Vs Conventional Radiotherapy for Patients with Stage II/III Non–small Cell Lung Cancer and Poor Performance Status
Iyengar, Puneeth, Elizabeth Zhang-Velten, Laurence Court, Kenneth Westover, Yulong Yan, Mu-Han Lin, Zhenyu Xiong, et al.. 2021. “Accelerated Hypofractionated Image-guided Vs Conventional Radiotherapy for Patients with Stage II/III Non–small Cell Lung Cancer and Poor Performance Status”. JAMA Oncology. American Medical Association (AMA). doi:10.1001/jamaoncol.2021.3186.
clinicaltrials.govStudy
Hypofractionated Image-Guided Radiation Therapy (IGRT) in Patients With Stage II-III Non-Small Cell Lung Cancer
Puneeth Iyengar 2012. "Hypofractionated Image-Guided Radiation Therapy (IGRT) in Patients With Stage II-III Non-Small Cell Lung Cancer". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT01459497.
~8 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top